Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Impact of diabetes education and self-management on the quality of care for people with type 1 diabetes mellitus in the Middle East (The International Diabetes Mellitus Practices Study, IDMPS).

José Gagliardino J, Chantelot JM, Domenger C, Ramachandran A, Kaddaha G, Claude Mbanya J, Shestakova M, Chan J; IDMPS Steering Committee.

Diabetes Res Clin Pract. 2018 Sep 12. pii: S0168-8227(18)30727-7. doi: 10.1016/j.diabres.2018.09.008. [Epub ahead of print]

PMID:
30218744
2.

Diabetes education and health insurance: how they affect the quality of care provided to people with type 1 diabetes in Latin America. Data from the International Diabetes Mellitus Practices Study (IDMPS).

José Gagliardino J, Chantelot JM, Domenger C, Ilkova H, Ramachandran A, Kaddaha G, Claude Mbanya J, Chan J, Aschner P; IDMPS Steering Committee.

Diabetes Res Clin Pract. 2018 Aug 14. pii: S0168-8227(18)30728-9. doi: 10.1016/j.diabres.2018.08.007. [Epub ahead of print]

PMID:
30118748
3.

Diabesity in the Arabian Gulf: Challenges and Opportunities.

Khalil AB, Beshyah SA, Abdella N, Afandi B, Al-Arouj MM, Al-Awadi F, Benbarka M, Ben Nakhi A, Fiad TM, Al Futaisi A, Hassoun AA, Hussein W, Kaddaha G, Ksseiry I, Al Lamki M, Madani AA, Saber FA, Abdel Aal Z, Morcos B, Saadi H.

Oman Med J. 2018 Jul;33(4):273-282. doi: 10.5001/omj.2018.53. Review. No abstract available.

4.

Liraglutide and Renal Outcomes in Type 2 Diabetes.

Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators.

N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.

5.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators.

N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.

6.

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators.

N Engl J Med. 2015 Dec 3;373(23):2247-57. doi: 10.1056/NEJMoa1509225.

7.

Driving and diabetes mellitus in the Gulf Cooperation Council countries: Call for action.

Hassoun AAK, Abdella N, Arouj MA, Awadi FA, Futaisi AA, Lamki MA, Madani AA, Saber FA, Nakhi AB, Beshyah SA, El-Ali S, Fiad TM, Hussein WI, Kaddaha G, Ksseiry I, Morcos B, Saadi H.

Diabetes Res Clin Pract. 2015 Oct;110(1):91-94. doi: 10.1016/j.diabres.2015.08.002. Epub 2015 Aug 22. Review.

PMID:
26345248
8.

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.

Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, Gerstein HC, Johnston P, Køber LV, Lawson F, Lewis EF, Maggioni AP, McMurray JJ, Ping L, Probstfield JL, Solomon SD, Tardif JC, Wu Y, Pfeffer MA; ELIXA Investigators.

Am Heart J. 2015 May;169(5):631-638.e7. doi: 10.1016/j.ahj.2015.02.002. Epub 2015 Feb 12.

PMID:
25965710
9.

The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial.

Al Sifri S, Basiounny A, Echtay A, Al Omari M, Harman-Boehm I, Kaddaha G, Al Tayeb K, Mahfouz AS, Al Elq A, Radican L, Ozesen C, Katzeff HL, Musser BJ, Suryawanshi S, Girman CJ, Davies MJ, Engel SS; 2010 Ramadan Study Group.

Int J Clin Pract. 2011 Nov;65(11):1132-40. doi: 10.1111/j.1742-1241.2011.02797.x. Epub 2011 Sep 27.

10.

Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study.

Aravind SR, Al Tayeb K, Ismail SB, Shehadeh N, Kaddaha G, Liu R, Balshaw R, Lesnikova N, Heisel O, Girman CJ, Musser BJ, Davies MJ, Katzeff HL, Engel SS, Radican L; 2009 Ramadan Study Group.

Curr Med Res Opin. 2011 Jun;27(6):1237-42. doi: 10.1185/03007995.2011.578245. Epub 2011 Apr 20.

PMID:
21506631
11.

Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial.

Zamorano J, Erdine S, Pavia A, Kim JH, Al-Khadra A, Westergaard M, Sutradhar S, Yunis C; CRUCIAL Investigators.

Curr Med Res Opin. 2011 Apr;27(4):821-33. doi: 10.1185/03007995.2011.555754. Epub 2011 Feb 10.

PMID:
21306285
12.

Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study.

Zamorano J, Erdine S, Lopez AP, Kim JH, Al Khadra A, Westergaard M, Sutradhar S, Yunis C; CRUCIAL Investigators.

Postgrad Med. 2010 Mar;122(2):7-15. doi: 10.3810/pgm.2010.03.2117.

PMID:
20203451
13.

Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.

Davies M, Lavalle-González F, Storms F, Gomis R; AT.LANTUS Study Group.

Diabetes Obes Metab. 2008 May;10(5):387-99. doi: 10.1111/j.1463-1326.2008.00873.x. Epub 2008 Mar 18.

PMID:
18355327
14.

Oral glucose tolerance and ambient temperature in non-diabetic subjects.

Akanji AO, Bruce M, Frayn K, Hockaday TD, Kaddaha GM.

Diabetologia. 1987 Jun;30(6):431-3.

PMID:
3678662

Supplemental Content

Loading ...
Support Center